Barclays PLC reduced its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 50.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 120,221 shares of the company's stock after selling 124,824 shares during the period. Barclays PLC owned 0.18% of EyePoint Pharmaceuticals worth $895,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Franklin Resources Inc. grew its holdings in shares of EyePoint Pharmaceuticals by 9.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock valued at $32,056,000 after acquiring an additional 362,399 shares in the last quarter. JPMorgan Chase & Co. grew its stake in EyePoint Pharmaceuticals by 1,171.3% in the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock valued at $2,970,000 after purchasing an additional 342,516 shares in the last quarter. Cyndeo Wealth Partners LLC grew its stake in EyePoint Pharmaceuticals by 35.5% in the fourth quarter. Cyndeo Wealth Partners LLC now owns 16,990 shares of the company's stock valued at $127,000 after purchasing an additional 4,450 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of EyePoint Pharmaceuticals by 40.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company's stock worth $108,000 after purchasing an additional 4,179 shares during the last quarter. Finally, abrdn plc bought a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter worth approximately $1,719,000. 99.41% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages recently weighed in on EYPT. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Chardan Capital reissued a "buy" rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $26.63.
Check Out Our Latest Report on EYPT
EyePoint Pharmaceuticals Trading Down 6.0 %
EyePoint Pharmaceuticals stock opened at $6.86 on Tuesday. The company has a market capitalization of $472.04 million, a price-to-earnings ratio of -3.43 and a beta of 1.39. EyePoint Pharmaceuticals, Inc. has a 12 month low of $3.91 and a 12 month high of $14.00. The stock's 50 day moving average is $6.02 and its 200-day moving average is $7.60.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. As a group, equities research analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.
EyePoint Pharmaceuticals Profile
(
Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
See Also
Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
